 | Q3 2020 EPS Estimates for ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Lifted by Jefferies Financial Group
www.americanbankingnews.com - December 12 at 6:41 AM |
 | Astellas Pharma Inc. -- Moody's reviews Astellas Pharma's A1 ratings for downgrade
finance.yahoo.com - December 6 at 9:59 AM |
| Astellas and MBC BioLabs Announce Golden Ticket Winners - Supporting Biotech Start-Ups to Accelerate Innovative Science
finance.yahoo.com - December 5 at 12:36 PM |
| ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Receiving Somewhat Favorable Press Coverage, Study Shows
www.americanbankingnews.com - December 4 at 11:20 PM |
| Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
finance.yahoo.com - December 2 at 11:54 PM |
| This Gene Therapy Player Just Grabbed A $3 Billion Takeover Bid
finance.yahoo.com - December 2 at 6:53 PM |
| Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Cancer
finance.yahoo.com - December 2 at 8:53 AM |
| Comparing ASTELLAS PHARMA/ADR (ALPMY) and The Competition
www.americanbankingnews.com - November 21 at 9:11 PM |
| New England Journal of Medicine Publishes Results from Astellas' Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia(1)
finance.yahoo.com - October 31 at 5:31 PM |
| U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury
finance.yahoo.com - October 28 at 1:51 PM |
 | The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug
www.benzinga.com - October 25 at 7:41 AM |
| European Commission Approves Astellas' XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
finance.yahoo.com - October 25 at 7:41 AM |
| Astellas Pharma Inc. -- Moody's announces completion of a periodic review of ratings of Astellas Pharma Inc.
finance.yahoo.com - October 16 at 1:39 PM |
| Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy
finance.yahoo.com - October 13 at 9:25 AM |
| Investors May Want to Follow the Progress of These Biotechs
finance.yahoo.com - September 23 at 8:27 PM |
| Astellas Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
finance.yahoo.com - September 20 at 1:11 PM |
| Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - September 16 at 9:29 AM |
| Astellas Partners with MBC BioLabs to Help Pioneering Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts
finance.yahoo.com - September 11 at 6:15 PM |
| Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales
finance.yahoo.com - July 10 at 9:31 AM |
| Seattle Genetics, Astellas drug rapidly shrinks tumors in bladder cancer study
finance.yahoo.com - June 3 at 5:52 PM |
| U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)
finance.yahoo.com - May 30 at 9:32 AM |
| New Data Show Mirabegron Reduced OAB Symptoms in Men with Benign Prostatic Hyperplasia Currently Treated with Tamsulosin
finance.yahoo.com - May 14 at 9:48 AM |
 | Amgen, Astrellas to pay $125 million in fines tied to alleged kickback scheme
www.marketwatch.com - April 25 at 6:12 PM |
| Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe
finance.yahoo.com - April 25 at 6:12 PM |
| Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
finance.yahoo.com - April 1 at 9:59 AM |
| Astellas Presents Fezolinetant Phase 2b Clinical Trial Results at Endocrine Society's Annual Meeting (ENDO)
finance.yahoo.com - March 26 at 6:25 PM |
| Why Ironwood's Shares Climbed 11.7% on Wednesday
finance.yahoo.com - February 13 at 5:40 PM |
| Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
finance.yahoo.com - February 11 at 5:37 PM |
| Can This Biotech Stock Rival Amgen In Anemia? Analyst Says Yes
finance.yahoo.com - December 20 at 4:48 PM |
| Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer
finance.yahoo.com - December 20 at 9:31 AM |
| Astellas Acquires Potenza Therapeutics
finance.yahoo.com - December 14 at 4:51 PM |
| Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
finance.yahoo.com - December 3 at 4:30 PM |
| XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation
finance.yahoo.com - November 29 at 9:50 AM |
| Astellas Pharma gets U.S. nod for blood cancer treatment
finance.yahoo.com - November 28 at 4:41 PM |
| Astellas Global Health Foundation Launches
finance.yahoo.com - November 20 at 4:35 PM |
| Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 19 at 9:13 AM |
| Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
finance.yahoo.com - September 24 at 9:26 AM |
| [$$] Astellas Pharma Buys U.K.'s Quethera
finance.yahoo.com - August 10 at 4:26 PM |
| Astellas Announces Acquisition of Quethera
finance.yahoo.com - August 10 at 9:31 AM |
| Astellas Is Considering Selling Europe Assets to Raise Cash
finance.yahoo.com - July 18 at 4:16 PM |
| U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
finance.yahoo.com - July 14 at 4:46 PM |
| Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
finance.yahoo.com - June 3 at 9:14 AM |
| Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World
finance.yahoo.com - May 31 at 4:31 PM |
| How Is Merck’s Hospital Acute Care Segment Positioned?
finance.yahoo.com - May 30 at 9:30 AM |
 | FDA accepts Astellas' marketing application for gilteritinib for AML
seekingalpha.com - May 29 at 4:28 PM |
 | Astellas Pharma: FDA To Review NDA For Gilteritinib - Quick Facts
www.nasdaq.com - May 29 at 9:17 AM |
| U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
finance.yahoo.com - May 29 at 9:17 AM |
| Astellas Announces Abstracts Highlighting Growing Oncology Portfolio to be Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 17 at 9:43 AM |
| Astellas Appoints Bernhardt Zeiher, M.D., as New Chief Medical Officer
finance.yahoo.com - May 15 at 4:48 PM |
| Astellas Pharma : FDA Approves Supplemental NDA For Myrbetriq
www.nasdaq.com - May 8 at 9:22 AM |
